Chimeric antigen receptor (CAR) T-cell therapy is a relatively new cancer treatment where a patient’s autologous T-cells are genetically modified in the laboratory to attack cancer cells, and then infused back into the patient. Milliman performed a detailed descriptive analysis to identify the characteristics and treatment patterns of potentially CAR T-cell therapy eligible adult relapsed/refractory disease B-cell lymphoma patients covered by commercial insurance or Medicare fee-for-service.

This report was commissioned by Gilead Sciences, Inc.